There are four main leading factors why researchers choose one journal publication over the other: reputation of the journal, relevance of the publication content, quality and transparency of the peer review process, and the journal’s readership influence and impact factor.In the Oncology and cancer research, one of the top publications that combine all of the highlighted factors is Oncotarget. To begin with, the journal is highly ranked as one of the top open-access journals globally—with an average impact factor of 5.0 for the past 5 years. Its editorial board is also comprised of reputed scholars and researchers, most of whom boasts of numerous accolades in the medical research world including the Breakthrough Prize and the Laser Prize.Oncotarget’s publication process is also straightforward and impartial: researchers and scholars who want their studies published can easily find the necessary information and resources that they need on Oncotarget’s website.While the primary focus of the publication is oncology, Oncotarget also publishes research papers in the fields of pathology, immunology, age-related diseases, and endocrinology. The Journal’s editors decided to publish papers in other fields as well to allow the researchers in these fields to also leverage on the success behind the publication.
Making scientific research widely available
Unlike other journals which require subscription, Oncotarget is free to access. In fact, each of their weekly issues can be printed on special demand.The publication’s mission is to make scientific research easily available by enhancing faster sharing of exceptional discoveries. The publication also aims at maximizing the impact of scientific research through capitalizing on insightful review. This subsidiary of Impact Journal is also focused at eliminating the border between different specialties and fostering application of clinical and basic science in fighting diseases.
This move has resulted into positive cross-border collaboration between researchers, something that wasn’t initially possible.One of the recent researches that Oncotarget published is an article on Salvage Therapy for Relapsed Testicular Cancer. The article has brought a lot of hope to patients diagnosed with testicular cancer and who were uncertain of the treatment options available. The article highlights some of the causes of this type of cancer as well as how it can be treated and prevented.